Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MicuRx Receives $7.8 Million for Phase I/II Trials of Novel Antimicrobial

publication date: Aug 13, 2020

MicuRx Pharma, a San Francisco-Shanghai anti-infectives company, received $7.8 million in non-dilutive funding to support development of MRX-8, a novel antimicrobial. MicuRx said MRX-8 belongs to the same class of antibiotics as colistin and polymyxin B (PMB), but it expects MRSX-8 will prove to have a better side effect profile. The funds came from a global anti-infectives partnership, CARB-X. Two days ago, MicuRx announced it raised $43 million in a Series D round. More details.....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here